Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Pediatric Hematology/Oncology
•
Leukemia
•
ALL
•
Hematology
How would you manage an early isolated CNS relapse in a pediatric patient with Ph positive ALL?
Related Questions
What are your top takeaways in Hematologic Malignancies from ASH 2024?
When following current COG ALL protocols with the addition of two courses of blinatumomab to treatment for SR and HR patients, how frequently should surveillance bone marrow and MRD evaluations be performed?
How will you utilize the PARADIGM study results from ASH 2025, comparing azacitidine/venetoclax to intensive induction chemotherapy for fit patients with newly diagnosed AML?
How can the integration of MRD assessments into treatment protocols be optimized to improve risk stratification and therapy decisions in T-ALL?
What is your standard for monitoring triglyceride level during therapy for ALL, particularly in regards to receiving pegaspargase?
Do you use G-CSF for a patient with ALL admitted for febrile neutropenia with prolonged count recovery?
What factors should be considered when deciding whether to omit radiation in pediatric/AYA patients receiving N+AVD, particularly regarding long-term outcomes and second malignancy risks?
How do you choose between the different available CAR-T cell therapy products for the treatment of relapsed Ph-negative ALL?
For patients with newly diagnosed unmutated CLL how will you decide between BTKi alone vs Ven/BTKi vs Ven/Obin vs Ven/Obin/Acalabrutinib?
How would you proceed for a patient who has completed therapy for classic Hodgkin lymphoma with overall great disease response, but with new FDG avid lymph node on PET that is not amenable to biopsy?
